Who makes simethicon?

simethicon is developed by Azienda Policlinico Umberto I.

What development phase is simethicon in?

simethicon is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

simethicon

Azienda Policlinico Umberto I · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	simethicon
Also known as	Panamir V
Sponsor	Azienda Policlinico Umberto I
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mucolytic Solution Before Upper Endoscopy (NA)
Small Bowel Cleansing for Capsule Endoscopy in Pediatric Patients (PHASE4)
Different Bowel Preparations for Colonoscopy In Children (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

simethicon CI brief — competitive landscape report
simethicon updates RSS · CI watch RSS
Azienda Policlinico Umberto I portfolio CI